Life sciences firm Cristal Therapeutics has named Jeroen Tonnaer as its chief business officer.
Tonnaer joins from Merck Sharp & Dohme, where he was executive director, head European external scientific affairs and worldwide licensing. He will be responsible for the company’s business development, partnering and licensing activities.
As a neuroscientist, Tonnaer has expansive experience in the sector, including senior positions such as head of discovery collaborations Europe and Schering-Plough and head of the department of drug metabolism and kinetics at Organon.
He additionally serves as founder and executive consultant for PharmProspect, which helps start-ups and biotech companies work with pharma.
Joost Holthuis, CEO at Cristal Therapeutics, commented: “I am delighted to welcome Jeroen to Cristal Therapeutics and look forward to working with him.
“Jeroen will strengthen our key existing business relationships and focus on finding, executing and fostering new partnering opportunities for Cristal Therapeutics.
Cristal Therapeutics works with a focus on developing novel nanotherapeutics against cancer and other diseases by using its CriPec platform.